| |
Pre-progression index drugs
|
Pre-progression concomitant drugs
|
Post-progression index drugs
|
Post-progression subsequent melanoma drugs
|
Post-progression concomitant drugs
|
Pre-progression drug costs
|
Post-progression drug costs
|
Total drug costs
|
|---|
|
UK analysis
|
|
NIVO + IPI (n = 177)
|
£135,584
|
£4994
|
£17,021
|
£54,096
|
£3262
|
£140,578
|
£74,379
|
£214,957
|
|
IPI (n = 167)
|
£66,115
|
£1081
|
£4413
|
£145,037
|
£4032
|
£67,196
|
£153,482
|
£220,678
|
|
NIVO (n = 170)
|
£109,653
|
£1621
|
£25,936
|
£99,448
|
£2843
|
£111,274
|
£128,266
|
£239,540
|
|
Difference (NIVO + IPI vs. IPI
|
105%
|
362%
|
286%
|
− 63%
|
− 19%
|
109%
|
− 52%
|
− 3%
|
|
Difference (NIVO + IPI vs. NIVO)
|
24%
|
208%
|
− 34%
|
− 46%
|
15%
|
26%
|
− 42%
|
− 10%
|
|
Germany analysis
|
|
NIVO + IPI (n = 177)
|
€133,743
|
€10,621
|
€17,106
|
€52,940
|
€8897
|
€144,364
|
€78,943
|
€223,307
|
|
IPI (n = 167)
|
€63,773
|
€2646
|
€4250
|
€152,395
|
€9865
|
€66,419
|
€166,510
|
€232,929
|
|
NIVO (n = 170)
|
€110,977
|
€5901
|
€26,235
|
€97,889
|
€7749
|
€116,878
|
€131,873
|
€248,751
|
|
Difference (NIVO + IPI vs. IPI
|
110%
|
301%
|
302%
|
− 65%
|
− 10%
|
117%
|
− 53%
|
− 4%
|
|
Difference (NIVO + IPI vs. NIVO)
|
21%
|
80%
|
− 35%
|
− 46%
|
15%
|
24%
|
− 40%
|
− 10%
|
- NIVO + IPI nivolumab + ipilimumab cohort, NIVO nivolumab monotherapy cohort, IPI ipilimumab monotherapy cohort
